OVID Articles, Ovid Therapeutics Inc. - From 06/22/24

NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or th...

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging over 200 points on Monday. The Dow traded up 0.57% to 38,807...

Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endp...

U.S. stocks traded mixed midway through trading, with the S&P 500 edging higher on Monday. The Dow traded up 0.08% to 38,618.63 while the NASDA...

U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 100 points on Monday. Following the market opening Monday, the Do...

Monday, Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the...

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose sharply in today's pre-market trading after the company announced results from its ongoi...

Alimera Sciences (NASDAQ: ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This comp...

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to co...

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to meaningfully improvi...